Browsing by Author "Domínguez Covarrubias, Francisco José"
Now showing 1 - 13 of 13
Results Per Page
Sort Options
- ItemCaracterísticas clínico-patológicas y sobrevida de pacientes con cáncer de mama bilateral sincrónico(2014) Sánchez Rojel, César Giovanni; Acevedo Claros, Francisco Nicolás; Petric, M.; Domínguez Covarrubias, Francisco José; León Ramírez, Augusto; Razmilic Valdés, Dravna Nichi; Ceballos, C.; Espinoza, F.; Navarro Ortega, María Elena; Oddo Benavides, David; Camus, M.
- ItemClinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study(2023) Acevedo Claros, Francisco Nicolás; Walbaum, Benjamin; Medina, Lidia; Merino Lara, Tomás Rodrigo; Camus Appuhn, Mauricio Gonzalo; Puschel Illanes, Klaus; Ramírez Parada, Karol Lilia; Manzor, Manuel; Veglia, Paulina; Martinez, Raul; Guerra, Constanza; Navarro, Marisel; Bauerle, Catherine; Domínguez Covarrubias, Francisco José; Sánchez Rojel, César GiovanniBackground Latin American (LA) studies on triple-negative breast cancer (TNBC) and their characteristics are scarce. This forces physicians to make clinical decisions based on data obtained from studies that include non-Hispanic patients. Our study sought to obtain local epidemiological data, including risk factors and clinical outcomes from a Chilean BC registry. Methods This was a retrospective population-cohort study that included patients treated at a community hospital (mid-low income) or an academic private center (high income), in the 2010-2021 period. Univariate and multivariate analyses were performed to identify prognostic factors associated with survival. Results 647 out of 5,806 BC patients (11.1%) were TNBC. These patients were younger (p = 0.0001) and displayed lower rates of screening-detected cases (p = 0.0001) compared to non-TNBC counterparts. Among TNBC patients, lower income (i. e., receiving treatment at a community hospital) was associated with poorer overall survival (HR: 1.53; p = 0.0001) and poorer BC specific survival (HR: 1.29; p = 0.004). Other risk factors showed no significant differences between TNBC and non-TNBC. As expected, 5-year OS was significantly shorter on TNBC versus non-TNBC patients (p = 0.00001). In our multivariate analyses TNBC subtype (HR: 2.30), locally advanced stage (HR: 7.04 for stage III), lower income (HR: 1.64), or non-screening detected BC (HR: 1.32) were associated with poorer OS. Conclusion To the best of our knowledge, this is the largest LA cohort of TNBC patients. Interestingly, the proportion of TNBC among Chileans was smaller compared to similar studies within LA. As expected, TNBC patients had poorer survival and higher risk for early recurrence versus non-TNBC. Other relevant findings include a higher proportion of premenopausal patients among TNBC. Also, mid/low-income patients that received medical attention at a community hospital displayed lower survival versus private health center counterparts.
- ItemCuándo y cómo realizar una biopsia de las lesiones cutáneas frecuentes. Lo que el cirujano debe saber(2015) Droppelmann Droppelmann, Katherine Ann; Cataldo C., Karina; Molgó Novell, Montserrat; Goñi Espíldora, Ignacio; León Ramírez, Augusto; Camus Appuhn, Mauricio Gonzalo; González Díaz, Hernán; Domínguez Covarrubias, Francisco José; Droppelmann, Nicolás
- ItemGranulomatous lobular mastitis associated with ductal carcinoma in situ of the breast(2019) Oddo Benavides, David; Domínguez Covarrubias, Francisco José; Gomez, N.; Méndez Olivieri, Gonzalo Patricio; Navarro Ortega, María Elena
- ItemImpacto de las metástasis del linfonodo centinela y su tamaño, en el tratamiento del cáncer de mama(2014) Escudero, N.; Jans J.; Leon, F.; León Ramírez, Augusto; Domínguez Covarrubias, Francisco José; Goñi Espíldora, Ignacio; Droppelmann, Nicolás; Sánchez Rojel, César Giovanni; Oddo Benavides, David; Camus Appuhn, Mauricio Gonzalo
- ItemIndicación de biopsia de linfonodo centinela en CDIS de mama. Estudio de factores predictivos de hallazgo de carcinoma invasor posoperatorio(Sociedad de Cirujanos de Chile, 2024) Guesalaga Ruiz-Tagle, Paz; Fernández Thiers, Sebastián José; Rodríguez Gutiérrez, Javier Ignacio; Camus Appuhn, Mauricio Gonzalo; Sánchez Rojel, César Giovanni; Acevedo Claros, Francisco Nicolás; Merino Lara, Tomás Rodrigo; Abud Pérez, Maritza Eugenia; Domínguez, Angélica; Domínguez Covarrubias, Francisco JoséIntroducción: El carcinoma ductal in situ (CDIS) de la mama es un precursor del carcinoma invasor, representando el 20-25% de los diagnósticos de cáncer de mama. La biopsia percutánea preoperatoria no siempre identifica focos de invasión, por lo que informe postoperatorio de carcinoma invasor implica otra cirugía para biopsia de linfonodo centinela (BLC). El objetivo del trabajo es analizar factores clínico-patológico-radiológicos de pacientes con diagnóstico preoperatorio de CDIS que permitan predecir el riesgo de carcinoma invasor postoperatorio y en quienes sería necesario realizar BLC para evitar otra cirugía. Métodos: Se realizó un estudio retrospectivo de 304 pacientes con diagnóstico preoperatorio de CDIS mediante biopsia percutánea en nuestra institución entre 2007 y 2021. La asociación entre las variables y el diagnóstico de carcinoma invasor en el postoperatorio fue analizada con modelos de regresión logística usando análisis univariado y multivariado. Resultados: Se identificaron 304 pacientes con diagnóstico de CDIS puro en la biopsia percutánea. De ellos, 85 (28%) presentaron carcinoma invasor en el análisis postoperatorio. En el análisis multivariado la edad (OR 1,06; IC 95% 1,01-1,11), tamaño de la lesión (OR 1,03; IC 95% 1,01-1,05) y receptores hormonales negativos (OR 5,47; IC 95% 1,61-18,56) resultaron estar asociados a un mayor riesgo de componente invasor postoperatorio. Conclusión: En pacientes con CDIS, las variables edad, tamaño y estado de receptores hormonales son factores pronósticos para encontrar invasión en el estudio postoperatorio. Por lo tanto, deben ser considerados al decidir el tratamiento quirúrgico.
- ItemInmunohistoquímica convencional como predictor de respuesta y sobrevida en pacientes con cáncer de mama tratadas con quimioterapia preoperatoria. Experiencia de un centro(2015) Acevedo Claros, Francisco Nicolás; Camus Appuhn, Mauricio Gonzalo; Vial, Catalina; Panay, Sergio; Abarca, Marcelo; Domínguez Covarrubias, Francisco José; Sánchez Rojel, César Giovanni
- ItemMedullary thyroid cancer. Review of 28 patients(2013) Pulgar, D.; Jans, J.; Petric, M.; León Ramírez, Augusto; Camus Appuhn, Mauricio Gonzalo; Goñi Espíldora, Ignacio; Domínguez Covarrubias, Francisco José; Droppelmann, Nicolás; González Díaz, Hernán; Claure Saavedra, Raúl
- ItemNuevas terapias sistémicas para el tratamiento del melanoma(2016) Droppelmann, Nicolás; León Ramírez, Augusto; Goñi Espíldora, Ignacio; González Díaz, Hernán; Domínguez Covarrubias, Francisco José; Camus Appuhn, Mauricio Gonzalo; Nervi Nattero, Bruno; Uribe González, Pablo Francisco; Molgó Novell, Montserrat; Acevedo Claros, Francisco Nicolás
- ItemReduction in the number of early melanomas diagnosed during the COVID‐19 pandemic: a single‐centre cohort study(2021) Koch Hein, Erica Cristina; Villanueva, Francisco; Marchetti, Michael A.; Abarzúa Araya, Álvaro Rodrigo; Cárdenas de la Torre, Consuelo Paz; Castro, Juan Camilo; Domínguez Covarrubias, Francisco José; Droppelmann, Katherine; Droppelmann, Nicolás; Galindo A., Héctor; León Ramírez, Augusto; Madrid Arenas, Jorge; Molgó Novell, Montserrat; Mondaca, Sebastián; Montero, Pablo H.; Uribe González, Pablo Francisco; Villaseca, Miguel A.; Vinés Vásquez, Eugenio; Navarrete Dechent, Cristian
- ItemRendimiento de la biopsia intraoperatoria por congelación en el estudio del linfonodo centinela en cáncer de mama(2013) Jans, J.; Escudero, N.; León, F.; León Ramírez, Augusto; Domínguez Covarrubias, Francisco José; Goñi Espíldora, Ignacio; Droppelmann, Nicolás; Sánchez Rojel, César Giovanni; Oddo Benavides, David; Alonso, P.; Ibáñez, F.; Camus, M.
- ItemRisk factors for loco-regional recurrence in breast cancer patients: A retrospective study(2018) Merino Lara, Tomas Rodrigo; Ip, Teresa; Domínguez Covarrubias, Francisco José; Acevedo Claros, Francisco Nicolás; Medina Araya, Lidia; Villarroel, Alejandra; Camus Appuhn, Mauricio Gonzalo; Vinés Vásquez, Eugenio; Sánchez Rojel, César Giovanni
- ItemSuboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study(2024) Heredia Castro, Ana Manuela; Walbaum García, Benjamín Vicente; Vidal, María ; Itriago Giménez, Laura Morella; Camus Appuhn, Mauricio Gonzalo; Domínguez Covarrubias, Francisco José; Manzor, Manuel ; Martínez, Raúl ; Murature, Geraldine ; Muñiz Muñoz, María Sabrina; Navarro, Marisel ; Guerra, Constanza ; Merino Lara, Tomás Rodrigo; Medina Araya, Lidia Marjorie; Ibáñez Cáceres, Carolina; Ramírez Parada, Karol Lilia; Acevedo Claros, Francisco Nicolás; Sánchez Rojel, César GiovanniPurpose The incidence of breast cancer in young women (BCYW) has increased in recent decades. Malignant disease in this subset is characterized by its aggressiveness and poor prognosis. Ovarian function suppression (OFS) in these patients improves survival especially in hormone receptor-positive (HR +) cases. The Regan Composite Risk (RCR) is a prognostic tool to identify high-risk HR + BC candidates for OFS. Our study sought to characterize a Chilean cohort of early HR + BCYW assessing the use of OFS and its related prognosis and the utility of RCR in our patients.MethodsThis was a retrospective population cohort study that included ≤ 35-year-old early HR + /human epidermal growth factor receptor 2 -negative (HER2-) BC patients treated between 2001 and 2021. Analysis included clinical-pathological characteristics, treatment strategies, and survival. Also, we evaluated the association between RCR and survival.ResultsA total of 143 patients were included into our study, representing 2.9% of all early BC cases in our registry. Median age was 31 years old (range: 19–35). Most patients (93%) received endocrine therapy (ET). Of these, 18% received OFS. No survival differences were observed among treatment strategies. Median RCR score for patients treated with CT plus ET was significantly higher vs. ET alone (2.95 vs. 1.91; p = 0.0001). Conversely, patients treated with tamoxifen alone had significantly lower RCR scores vs. OFS (2.72 vs. 3.14; p = 0.04). Higher RCR scores were associated with poorer overall survival.ConclusionLess than 20% of very young women with early HR + /HER2-BC in our cohort received OFS, in most cases, this involved surgical oophorectomy. RCR score was higher in patients that underwent CT and OFS and was associated with survival, regardless of treatment. We confirm the RCR score as a valuable prognostic tool to identify high-risk BC patients who could benefit from OFS.